Treatment in Autoimmune Disease
Anokion is an innovative immune tolerance company focused on providing a more effective approach to treating autoimmune disease. Our proprietary immune tolerance platform features proteins, or antigens, that are engineered to deliver precise, targeted disease therapy, without the side effects of broad immunosuppression. Anokion’s antigen-specific platform can be translated to virtually any antigen-mediated disease, with widespread potential across multiple clinical applications.
- September 13, 2019
Anokion Presents New Data Describing Transformative Therapeutic Approach for Treatment of Multiple Sclerosis at ECTRIMS Congress| Read More
- September 11, 2019
Anokion Acquires Kanyos Bio and Raises $40 Million to Advance First Product Candidate into Clinic in 2019| Read More